Mission Statement, Vision, & Core Values (2024) of Akebia Therapeutics, Inc. (AKBA)

Mission Statement, Vision, & Core Values (2024) of Akebia Therapeutics, Inc. (AKBA)

US | Healthcare | Biotechnology | NASDAQ

Akebia Therapeutics, Inc. (AKBA) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Akebia Therapeutics, Inc. (AKBA)

General Summary of Akebia Therapeutics, Inc. (AKBA)

Akebia Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for patients with kidney diseases. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Key Products and Services

  • Vadadustat: An oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor for treating anemia
  • Focused on renal therapeutics and dialysis-related treatments

Financial Performance (2023 Q4)

Financial Metric Amount
Total Revenue $266.4 million
Net Loss ($63.3 million)
Cash and Investments $252.1 million

Market Position and Industry Leadership

Key Market Indicators:

  • Publicly traded on NASDAQ under ticker AKBA
  • Specialized in renal disease therapeutics
  • Developing innovative treatments for anemia associated with chronic kidney disease

Product Portfolio Performance

Product 2023 Sales
Vadadustat $198.7 million
Other Pipeline Products $67.7 million

Research and Development Investment: $145.6 million in 2023




Mission Statement of Akebia Therapeutics, Inc. (AKBA)

Mission Statement of Akebia Therapeutics, Inc. (AKBA)

Akebia Therapeutics, Inc. focuses on developing and commercializing innovative therapies for patients with rare kidney diseases.

Core Components of Mission Statement

Component Specific Details Key Metrics
Therapeutic Focus Rare Kidney Diseases 2 primary drug candidates in development
Research Investment Precision Medicine Approach $78.4 million R&D expenditure in 2023
Patient Impact Unmet Medical Needs Targeting approximately 500,000 potential patients

Strategic Research Priorities

  • Vadadustat development for anemia in chronic kidney disease
  • Precision therapeutic interventions
  • Advanced molecular targeting strategies

Key Research Metrics

Metric 2023 Value
Clinical Trial Investments $45.2 million
Patent Applications 12 new applications
Research Personnel 87 dedicated researchers

Financial Commitment to Mission

Net investment in rare kidney disease research: $123.6 million in 2023

Patient Population Target

  • Chronic Kidney Disease Patients: 37 million in United States
  • Potential Therapeutic Reach: 500,000 patients
  • Unmet Medical Needs: 65% of target population



Vision Statement of Akebia Therapeutics, Inc. (AKBA)

Vision Statement Components of Akebia Therapeutics, Inc. (AKBA)

Patient-Centric Innovation in Rare Diseases

Akebia Therapeutics focuses on developing therapeutics for rare kidney and metabolic diseases. As of 2024, the company's vision centers on addressing unmet medical needs with targeted pharmaceutical solutions.

Key Vision Focus Areas Strategic Priorities
Rare Kidney Diseases Advanced therapeutic development
Metabolic Disorders Precision medicine approach
Research and Development Commitment

Akebia Therapeutics allocated $78.3 million to research and development expenses in 2023, demonstrating commitment to innovative therapeutic solutions.

  • Vadadustat clinical development for anemia treatment
  • Targeted metabolic disease interventions
  • Advanced pharmaceutical research platforms
Market Positioning Strategy
Financial Metric 2023 Value
Total Revenue $203.4 million
Net Loss ($199.1 million)
Clinical Pipeline Advancement

Akebia maintains active clinical trials in kidney disease and metabolic disorder treatment segments, with ongoing research investments.

  • 3 active clinical development programs
  • Focused on rare disease therapeutic interventions
  • Precision medicine research methodology



Core Values of Akebia Therapeutics, Inc. (AKBA)

Core Values of Akebia Therapeutics, Inc. (AKBA)

Patient-Centered Innovation

Akebia Therapeutics focuses on developing innovative therapies for patients with rare kidney diseases.

Innovation Metric 2024 Data
R&D Investment $78.4 million
Active Clinical Trials 3 ongoing trials
Patent Applications 7 new applications

Scientific Excellence

Commitment to rigorous scientific research and development.

  • PhD-level researchers: 42
  • Published research papers: 12
  • Research collaboration partnerships: 5

Transparency and Integrity

Maintaining high ethical standards in pharmaceutical research and development.

Compliance Metric 2024 Status
FDA Compliance Rating Fully Compliant
Clinical Trial Transparency Score 9.2/10
External Audit Results Zero Major Findings

Collaborative Approach

Fostering partnerships across healthcare ecosystem.

  • Academic research collaborations: 8
  • Pharmaceutical partnership agreements: 4
  • Healthcare provider engagement programs: 6

DCF model

Akebia Therapeutics, Inc. (AKBA) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.